Since TWEAK might promote cancer cell survival, a monoclonal antibody developed to block the TWEAK receptor (enabatuzumab) is being tested clinically in cancer trials (Lam and others 2018), although it has possible hepatotoxic effects. This evidence concerns the gene TNFSF12 and cancer.